TAVI or Surgery? How TAVI and SAVR Are Chosen in Aortic Stenosis

What is aortic stenosis?

Aortic stenosis is narrowing of the aortic valve that restricts blood flow from the left ventricle to the aorta. In severe aortic stenosis, breathlessness, chest pain, syncope or reduced exercise capacity may occur. Treatment need depends on severity and symptoms; not every stenosis requires the same procedure at the same time.

What is TAVI?

TAVI (Transcatheter Aortic Valve Implantation) places a bioprosthetic valve inside the diseased aortic valve through a catheter. The same approach is also called TAVR (Transcatheter Aortic Valve Replacement); TAVI and TAVR describe the same family of treatment.

Most procedures use femoral-artery (transfemoral) access and do not require sternotomy or classic open-heart surgery. Calling TAVI “surgery-free” is not absolute; it is a catheter-based / minimally invasive intervention and still carries procedural risk. TAVI uses bioprosthetic valves only.

What is surgical aortic valve replacement (SAVR)?

SAVR (Surgical Aortic Valve Replacement) removes the diseased aortic valve surgically and implants a mechanical or bioprosthetic valve. When a mechanical valve is clinically preferred, TAVI is not an alternative to mechanical replacement. Concurrent aortic-root / ascending-aorta surgery or coronary artery bypass grafting (CABG) can be planned in the same sitting when needed.

TAVI or surgery: what do current guidelines say?

The primary European frame for this guide is the 2025 ESC/EACTS Valvular Heart Disease guideline, which replaces the 2021 ESC/EACTS document:

• ≥70 years, tricuspid aortic valve and anatomy suitable for TAVI: TAVI is recommended (Class I, Level A).
• <70 years and low surgical risk: SAVR is recommended (Class I, Level B).
• For other bioprosthetic aortic-valve candidates, TAVI or SAVR is decided by the Heart Team using clinical status, anatomy, procedural risk, life expectancy, lifetime management and patient preference.

Much of the trial advantage for TAVI was shown with transfemoral TAVI; suitability of vascular access is an important part of the decision.

The 2020 ACC/AHA guideline is a complementary US perspective: SAVR if age <65 or expected survival >20 years; shared decision if age 65–80 with symptomatic severe AS and no barrier to transfemoral TAVI; prefer TF-TAVI if age >80 or life expectancy <10 years and TF-TAVI is suitable. European and American age thresholds are not identical; new shared cut-offs should not be invented.

What does the age-70 threshold mean?

The 2025 ESC/EACTS age-70 threshold is read with tricuspid-valve and suitable-anatomy conditions; age alone does not decide. Unsuitable anatomy, bicuspid valve, high coronary-obstruction risk or lifetime-management arguments for SAVR can change the choice independent of age. Likewise, selected higher-risk patients under 70 may still be discussed for TAVI.

When may TAVI be more suitable?

Factors that can influence Heart Team discussion — not an automatic indication list — include:

• ≥70 years + tricuspid aortic valve + suitable anatomy
• Suitable transfemoral vascular access
• Increased surgical risk
• Clinical importance of faster recovery
• Porcelain aorta and other conditions that complicate surgery
• Prior CABG with patent grafts that may make repeat sternotomy more difficult in some patients

Each factor gains or loses weight by patient; none alone proves that “TAVI must be done.”

When may surgery be more suitable?

Situations in which SAVR is more often discussed (still individualised) include:

• <70 years + low surgical risk
• Longer life expectancy / need for lifetime management
• Need for a mechanical valve
• Bicuspid aortic valve, especially in younger patients
• Bicuspid valve with aortopathy
• Need for ascending-aorta / root surgery
• Annulus or vascular anatomy unsuitable for TAVI
• High risk of coronary obstruction with TAVI
• Complex coronary disease needing CABG
• Need for another valve or cardiac operation in the same sitting

Can TAVI be performed for bicuspid aortic valve?

Most patients with bicuspid aortic valve (BAV) were excluded from landmark TAVI–SAVR randomised trials. Bicuspid anatomy can be more complex for TAVI because of asymmetric calcification, elliptical annulus, calcified raphe and coexisting aortopathy.

SAVR remains the mainstay especially in younger patients, those with aortopathy or unfavourable valve anatomy. TAVI may be considered by a Heart Team in selected BAV patients — particularly with higher surgical risk — when anatomy is suitable. It is neither “impossible” nor routinely equivalent to SAVR.

Key differences between TAVI and surgery

Within heart-valve interventions, TAVI and SAVR follow different pathways. The table summarises typical differences without declaring a winner.

In the 2025 ESC/EACTS frame, vascular complications, paravalvular leak and — especially with some self-expanding systems — new permanent pacemaker are more often seen after TAVI. Major bleeding, acute kidney injury, new atrial fibrillation and longer stay/recovery are more often discussed after SAVR. Absolute claims such as “risk-free,” “easier” or “safer for everyone” are not appropriate.

What did PARTNER 3 show at 7 years?

The PARTNER 3 7-year analysis included 1,000 selected low-surgical-risk patients with severe symptomatic aortic stenosis suitable for TAVI. The composite of death, stroke or valve- / procedure-related heart-failure hospitalisation was 34.6% with TAVR and 37.2% with surgery; the difference was not statistically significant. Death was 19.5% vs 16.8%; stroke 8.5% vs 8.1%; rehospitalisation 20.6% vs 23.5%; bioprosthetic valve failure 6.9% vs 7.5%.

These results do not mean “TAVI is better than surgery” or “the two methods are identical.” The trial enrolled selected low-risk patients with anatomy suitable for TAVI.

What did Evolut Low Risk show at 5 years?

In the Evolut Low Risk 5-year analysis of 1,414 patients (mean age about 74), all-cause mortality or disabling stroke was 15.5% with TAVR and 16.4% with surgery (p=0.47). All-cause mortality was 13.5% vs 14.9%; disabling stroke 3.6% vs 4.0%; valve reintervention 3.3% vs 2.5%. No significant difference was shown for the primary endpoint at 5 years. Findings are interpreted in the context of self-expanding TAVI.

What does NOTION’s 10-year data tell us?

NOTION reported a 10-year death/stroke/MI rate of 65.5% for both TAVI and SAVR in 280 patients (mean age about 79; mostly low surgical risk). Bioprosthetic valve failure was 9.7% with TAVI and 13.8% with SAVR (no significant difference); severe structural valve deterioration was 1.5% vs 10.0%.

The trial is small, includes older patients and earlier-generation prostheses. It should not be read as proof that “a TAVI valve lasts 10 years for sure” or that “lifetime durability in young patients is proven.” Durability is kept limited in this guide; the current 7- and 10-year frame is covered in detail in How long does a TAVI valve last?.

Why does TAVI durability matter especially in younger patients?

When expected survival may outlast prosthesis durability, the first valve choice shapes later options. Short-term trials (for example DEDICATE: death or stroke at 1 year 5.4% with TAVI vs 10.0% with SAVR; TAVI met noninferiority) can look favourable early, but long-term decisions should not rest on one-year data alone. Lifetime management includes CT-based planning, prosthesis–patient mismatch, small annulus and future coronary access.

Can another valve procedure be done after TAVI?

Valve-in-valve or TAV-in-TAV may be considered in selected patients. A second TAVI is not automatically feasible in every anatomy. Coronary obstruction risk, future coronary access, annular size and the first prosthesis type can limit options. TAVI explant surgery can also be technically demanding. The 2025 ESC/EACTS guideline therefore emphasises CT-based lifetime planning, especially when life expectancy may exceed prosthesis durability.

Does coronary artery disease change the decision?

Simple / non-complex coronary disease can be managed with PCI / stenting in some patients; assessment often includes coronary angiography. Complex coronary disease needing CABG may favour SAVR + CABG. TAVI + PCI versus SAVR + CABG should not be reduced to a superficial “which is better” comparison; anatomy and the goal of complete revascularization matter.

What is the Heart Team?

A Heart Team is a multidisciplinary review involving interventional cardiology, cardiac surgery and related clinicians. When both TAVI and SAVR are technically feasible, clinical status, anatomy, procedural risk, life expectancy, lifetime management, local expertise and patient preference are considered together. The aim is not to declare a winner but to choose the path that fits the individual.

In brief: TAVI or SAVR?

For aortic stenosis, the choice between TAVI and surgical aortic valve replacement is not made by age alone. Valve anatomy, surgical risk, transfemoral access, life expectancy, comorbidities and future valve planning are assessed together. The 2025 ESC/EACTS guideline favours TAVI at ≥70 years with suitable anatomy and SAVR at <70 years with low risk; remaining patients are individualised by the Heart Team. Randomised trials report balanced mid- to long-term results in selected cohorts; they do not justify universal superiority or equivalence claims.